MYRIAD GENETICS Business Summary

Myriad Genetics Inc. (MYGN) operates a molecular diagnostics business model, generating revenue primarily through transaction-based fees for its proprietary genetic testing services. The company’s operations are organized into three core business segments: Oncology, which includes hereditary cancer risk assessment and molecular residual disease (MRD) testing; Women’s Health, focusing on non-invasive prenatal testing (NIPT) and carrier screening; and Mental Health, centered on the GeneSight pharmacogenomics platform. For the fiscal year 2026, Myriad projects total revenues between $860 million and $880 million, driven by a strategic pivot toward high-growth precision medicine and liquid biopsy applications. The company faces intense competition from direct rivals such as Natera, Labcorp, Quest Diagnostics, and Ambry Genetics, maintaining a market position as a legacy leader in hereditary cancer while aggressively expanding its footprint in the rapidly evolving MRD and companion diagnostics sectors. The company was founded in 1991 by a distinguished team including Peter Meldrum, Dr. Mark Skolnick (inventor of RFLP gene mapping), Nobel Laureate Walter Gilbert, and Kevin Kimberlin. Current leadership is headed by President and CEO Sam Raha, who assumed the role in April 2025 following senior leadership tenures at Agilent and Illumina. He is supported by CFO Ben Wheeler, a 14-year company veteran promoted in August 2025, and COO Mark S. Verratti, who previously led the Mental Health division. The executive team also includes Chief Scientific Officer Dr. Dale Muzzey and Chief Technology Officer Dr. Kevin R. Haas. Myriad is overseen by a board chaired by S. Louise Phanstiel and maintains a high degree of institutional backing, with major stakeholders including BlackRock, The Vanguard Group, and State Street Global Advisors collectively holding over 95% of the company's outstanding shares.